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Clinical Trial Design
Dr. Lynch: If you do selection trials, what do you do with the
patient who might have a five percent or three percent
likelihood of responding to the drug - when you don’t have
very many other treatment options for them?
Dr. Govindan: One problem is that both the physician and
the patient are loath to not do something. Also, we have to
recognize that everything isn’t going to be solved by selec-
tion. When we don’t know, we should put them on a Phase 1
study with agents we are still trying to assess. We’ve got to
have a sequential approach when we don’t have a biomarker
identified.
Dr. Lynch: How are we going to handle the increasing
numbers of drugs that may work well on 2-3% of patients?
Dr. Shepherd: If we were able to develop a chip that had the
most important markers for lung cancer, it would then be
important to obtain tissue from all patients for molecular
testing. Based on the results we would be able to pair patients
with the right drug or drugs.
Dr. Lynch: How feasible is that?
Dr. Janne: I think it’s pretty feasible. There are good
technologies, for example mass spectrometry, that can geno-
type in hours, can do multiple genes simultaneously, and the
cost is nowhere near what it is to do sequencing. If you start
incorporating that sort of effort systematically, you will find
the few patients with the RAF mutations or PI3 kinase
mutations. But I think the other mindset issue, or problem is,
maybe we need to start getting core biopsies or bigger
biopsies, because we’re not going to be able to do all our
studies from fine needle aspiration biopsies.
Dr. Lynch: So if we are going to be doing targeted therapies,
we’re going to need more tissue. What do people think about
this?
Dr. Sorensen: I think core biopsies are certainly feasible
from a technical perspective. However, everybody resists
doing them. Even in our institution where we’ve done a lot of
them and done them safely, the radiologists resist doing
biopsies if they don’t have to, because there is increased risk
of complications such as pneumothorax.
Dr. Heymach: Regarding the biopsy issue, with the
BATTLE trial, we’ve actually been able to obtain core
biopsies in about 100 patients that are post-first line treatment
without significant problems. Regarding the point of selec-
tion, I’d argue that if patient selection happens, it should be
relatively late in the process, and I would argue for negative
selection for drugs that have at least some benefit for the
overall population. I think if you are doing early selection you
can sub-divide the populations inappropriately.
Dr. Natale: For the second generation tyrosine kinase inhib-
itors part of the selection criteria for entering their resistant
follow-on studies to imatinib, was to take patients who
weren’t just intolerant or clinically resistant, but who had an
emerging mutation.
Dr. Lynch: Is it possible to do a study in all patients with
B-RAF mutations, or PI3 kinase mutations, irrespective of
histology?
Dr. Janne: At one level I think it’s feasible. The question is
how you develop a drug, because in one cancer that biomar-
ker may have a predictive value and a prognostic value, and
in another cancer is may have a predictive value only. Also,
it may get more challenging to show a benefit across muta-
tions, because there’s so much variability across the cancers.
Dr. Lilenbaum: I think it’s really an issue of resources
because both endeavors need to be pursued. We’re probably
a long time away from being able to identify specific pathway
drivers for most patients with NSCLC. So while we can make
a difference in some specific subsets, the numbers are small.
We still have a large population who desperately need better
therapies. How you do that is not so much based on the
science, but its how you allocate the resources both from
government and industry. Think about angiogenesis. As a
pathway, and as a target, it’s way broader than I think the
EGFR is. So maybe there are one or two other pathways like
that, that may make a much bigger difference.
Dr. Hanke: It’s very difficult to get a really accurate positive
predictor. But more often we can come up with a negative
one. An example is K-RAS for EGFR agents. One approach
is to use such negative predictors to enrich for patients more
likely to respond, increase the power of your study, get
approval, and then focus on positive predictors in later clin-
ical trials.
Dr. Janne: But sometimes I think you get into the problem
that you do a Phase 1 trial, you include six lung cancer
patients, and you don’t see any response in that group. Then
the development strategy excludes lung cancer going forward
which may not be the right thing to do. You don’t always
know the correct negative strategy.
Dr. Engelman: I think that whether you go for positive or
negative predictor values should be assessed situation by
situation. I think K-RAS is a great example of a negative. I
think HER2 FISH is a great example of a positive, so I don’t
think every target or every drug should necessarily have the
same kind of strategy.
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Cooperative Group Studies
Dr. Lilenbaum: There’s no doubt in anybody’s mind that
most of the changes that have occurred in the management of
lung cancer in the past decade or two perhaps, came from the
cooperative groups. But it’s a nightmare to put a Phase 2
study through the cooperative group systems. And that should
change, because if it doesn’t fewer and fewer innovative
studies will get done through the cooperative framework.
Dr. Lynch: It does look as though all of the fabulous
cooperative group studies are Phase 3 trials.
Dr. Lilenbaum: Phase 2 studies have become unmanageable,
really, in the current system. And if the cooperative groups
are going to move forward with this, bring institutional ideas
and independent young investigators to develop those studies
that can potentially lead to Phase 3 trials, that system has to
be revamped, completely. Another challenge is to identify the
Phase 3 trials that accomplished nothing, and that, in retro-
spect, should not have been done had a more rigorous
scientific review process been in place. I think that would be
an important opportunity for us to learn from our own
mistakes.
Dr. Heymach: So how do you balance the advantages of
doing a study through the cooperative group process, with a
year lost to bureaucracy, versus a doing the study with
industry support? Are those advantages worth the year lost?
Dr. Wakelee:Well, I think it’s worth doing the study through
the cooperative group because many people are able to be
involved in the design and implementation of the study,
where otherwise it is handed down. Yes, industry seeks input
but at the end of the day, it is someone at the company who
writes and is in charge of the study.
Dr. Natale: Another important issue for the cooperative
groups to consider is that FDA is starting to require collection
of more safety data. Because “industry” is getting challenged
by the FDA, their representatives are going to challenge the
cooperative groups to improve their safety data reports, and if
that’s not changed, fewer companies will come to the coop-
erative groups to do registration studies.
Dr. Wakelee: I hear you, and I agree this is very important
point, but I don’t think it’s just an issue within the coopera-
tive groups. We may need to find some middle ground. But
I’m pretty comfortable with the safety data that we are
collecting with 1505.
Dr. Shapiro: In a Phase 2 study of a novel agent, there may
be quite a bit more safety data required, necessitating tests
that are not considered standard of care, so that one of the
major issues is funding.
Dr. Lynch: Yes, along the same lines, at Mass General it
costs us several times more than we get from cooperative
groups for doing studies. So if you start requiring the phar-
maceutical level of detail on the case report forms, you can’t
do it for $2,500 a patient. I worry about what’s happening in
cooperative groups, precisely because they have accom-
plished so much and I believe that their role is severely
threatened by the economics of clinical research in 2008. Do
you think we would be better off with one or two large
cooperative groups, or do you think having several competing
cooperative groups serves patients well?
Dr. Wakelee: If we didn’t have the ongoing healthy compe-
tition between the groups, I think that things would slow
down. Also, I would argue that one of the unique strengths of
the cooperative group system is that it allows scholarly
activities for people who don’t necessarily have their own
huge group of patients that have been accrued over the years,
that they can go back and look at, and do data mining. I think
that if you only have one big group, the competition within
such a large group to access patients and do studies and train
young physicians, would be difficult.
Dr. Hanna: Yes, and it’s hard to get people to agree on one
thing. It is interesting though, that when ECOG presents the
4599 study, it becomes the ECOG standard, but it’s not the
SWOG standard, and it’s not the CALGB standard. So it is
kind of weird how you gain ownership of a regimen because
your group did it.
Dr. Shepherd: I really think that the US system is so
hamstrung by process and rules that there is no ability to be
nimble. It is going to be critical to be able to cooperate
globally in the near future. The cooperative groups need to
rise to the challenge, but the US NCI and the US FDA should
be moving to facilitate opening US trials to other cooperative
groups worldwide. The rules that preclude global participa-
tion are going to leave the U.S. groups behind in the long run.
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Drug Combinations
Dr. Lilenbaum: So we’ve all seen the slide that lists 10
negative trials conducted in the past five to 10 years, basically
a combination of doublet plus or minus a targeted agent.
Many of them were sponsored and actually conducted under
the auspices of the pharmaceutical industry, and the record is
dismal, absolutely dismal. We have one positive study, per-
haps a second one, after 10,000 patients, and I can’t estimate
how many millions of dollars. There’s got to be a more
efficacious way to do this.
Dr. Lynch: I would argue that the clinical researchers are just
as responsible as the companies. Because of the competitive
nature of clinical research, wanting to get our hands on a
drug, we will say yes to a trial when the preclinical data is less
than compelling because we’ve been conditioned to learn that
the preclinical data doesn’t necessarily predict outcome, and
that even Phase 1 and 2 data can’t be trusted.
Dr. Hanna: I think one of the features of almost every
negative study was single arm Phase 2’s, or in some cases,
no Phase 2’s: just Phase 1’s then a jump to Phase 3. The
thing that the FLEX trial and the E4599 have in common
is they were both preceded by positive, randomized, Phase
2 studies. I think our hit rate is likely to be much higher if
we demand positive, randomized Phase 2’s, before going
to Phase 3.
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